# Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

> **NCT03407170** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1 (actual)

## Conditions studied

- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT03407170
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-28
- **Primary completion:** 2019-08-14
- **Final completion:** 2019-08-14
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03407170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03407170, "Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03407170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*